Diabetic Nephropathy & Hypertension

Diabetic nephrosis is characterized by cardiovascular disease, progressive proteinuria, glomerulosclerosis, and decline in capillary vessel filtration rate (GFR) resulting in ESRD. Cardiovascular disease within the setting of polygenic disease is outlined as a pulse force per unit area force per unit area mmHg or a pulsation force per unit area force per unit area mmHg. associate elevated urinary simple protein excretion rate, exaggerated force per unit area (BP), and a continuous loss of excretory organ operate are characteristics of DN. Screening for small proteinuria is central to polygenic disease care, and antihypertensive drug agents are used for the first interference and treatment of DN. Angiotensin-converting accelerator inhibitors and angiotnin receptor blockers play central roles and have protecting properties on the far side their BP-lowering effects. BP management in relevancy DN is that the main focus of this review, however tight management of the aldohexose level is equally vital.

  • Hypertension Management
  • Pathogenesis of diabetic nephropathy
  • Hypertension-Clinical and Experimental Models
  • Diabetic Nephropathy–Biomarkers of Disease

Related Conference of Diabetic Nephropathy & Hypertension

November 13-14, 2024

9th World Kidney Congress

Dubai, UAE
March 17-18, 2025

9th Global Summit onNephrology, Urology and Kidney Transplantation

Singapore City, Singapore
March 24-25, 2025

21st World Nephrology Conference

Amsterdam, Netherlands
May 26-27, 2025

29th European Nephrology Conference

Rome, Italy
June 23-24, 2025

26th Global Nephrology, Urology and Kidney Failure Congress

Aix-en-Provence, France

Diabetic Nephropathy & Hypertension Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in